Chair in Immunology

Brisbane, Australia
06 Apr 2018
End of advertisement period
06 May 2018
Contract Type
Fixed Term
Full Time

Faculty of Medicine

The University of Queensland’s Faculty of Medicine is an internationally recognised provider of world-class education and research. The research-intensive Faculty has a gross budget of almost $300 million, employs approximately 1000 continuing and fixed-term staff (headcount), has a community of more than 4000 non-salaried academic appointees and around 3200 students (headcount).

The Faculty of Medicine welcomes approximately 500 new medical students each year via graduate and school-leaver pathways. Undergraduate and postgraduate programs are available in the disciplines of Medicine, Health Sciences, E-Health, Mental Health, Biomedical Sciences and Public Health.

The Faculty possesses enormous strengths spanning research, teaching, industry engagement and clinical practice in disciplines ranging from the basic sciences, biomedical research and development, to clinical trials and public health. Research projects within the Faculty have already led to discoveries with far-reaching social and economic impacts, including the revolutionary Gardasil (TM) vaccine for cervical cancer (Professor Ian Frazer). Faculty staff include three highly cited authors, one Fellow of the Royal Society (FRS), three Fellows of the Australian Academy of Science (FAA) and 12 Fellows of the Academy of Health and Medical Sciences (AAHMS). The Faculty is a core member of Brisbane Diamantina Health Partners, the Brisbane-wide academic health science system.

Educational offerings in biomedical sciences, medicine and public health are informed and supported by research activity across a range of fundamental and clinical areas of importance including recognised strengths in cancer, skin diseases, brain and mental health, maternal and child health and genomics. Cutting-edge facilities such as the Herston Imaging Research Facility (HIRF), the UQ Centre for Clinical Research (UQCCR), our laboratories in the Translational Research Institute (TRI) and the new Centre for Children’s Health Research (CCHR) enable outstanding research outcomes and sharpen our understanding of cancer, autoimmunity, mental disorders, infectious diseases and neurological disease. Further details are available at

The University of Queensland Diamantina Institute

The University of Queensland Diamantina Institute (UQDI) was established in 2007 and forms a major research centre within the Faculty of Medicine. The aim of the Institute is to develop a better understanding of the molecular and cellular basis of disease, and to translate that understanding into practical outcomes for patients. Based at the Translational Research Institute (TRI) at the Princess Alexandra Hospital teaching campus in Brisbane, UQDI has more than 300 researchers, clinical academics and students who work closely with hospital clinicians in the areas of cancer, immunology, genomics and other areas of translational medicine.  UQDI has particular research strengths in skin cancers, blood cancers and autoimmunity.

UQDI has a mission of translating discoveries into better treatments and has a strong record of achievement, most notably in the development of cancer therapies: research at UQDI by Professor Ian Frazer AC FRS led to the development of the cervical cancer vaccine Gardasil. UQDI is the largest partner in the TRI, which is an extremely well-equipped translational biomedical research institute, with outstanding laboratories and core facilities for imaging, microscopy, flow-cytometry and in vivo models of disease. Its close affiliation with clinical units at Princess Alexandra Hospital provides UQDI with a significant strategic advantage in near-patient, translational research. 

UQDI is part of The University of Queensland, one of the top Australasian universities, and internationally is ranked in the top 100 universities in all major independent rankings. UQDI academics are part of a vibrant and highly successful academic institution optimising their chances of research success. Details of the research interests of academic staff may be accessed on the Institute’s web site at

The role This Endowed Chair will be established to honour the development of the cervical cancer vaccine Gardasil from research conducted at The University of Queensland by Professor Ian Frazer AC FRS.   

The Chair in Immunology will establish and lead a research group of international standing conducting high quality research in the field of Immunology with application to cancer or other diseases. The Chair will engage in collaborative research with other members of the UQ Diamantina Institute and other groups within the Faculty of Medicine to maximise opportunities for research outcomes. The person The Chair in Immunology will be an exceptional researcher and leader who will drive the development of a research program with translational potential in Immunology. It would be advantageous if the candidate shared our excitement about current and future applications of Immunology in the field of cancer (particularly skin cancer and haematological malignancy). Applications from outstanding clinical or non-clinical qualified researchers with strong competitive grant track records and excellent publications are welcomed. This is a research focused position.

The University of Queensland values diversity and inclusion. 

Applications are particularly encouraged from Aboriginal and Torres Strait Islander peoples. For further information please contact our Australian Indigenous Employment Coordinator at:  

Applications are also encouraged from women.


This is a full time, fixed term appointment at Research Academic Level E.  The initial appointment will be for a term of five years.  A further appointment may be offered following a review at least one year before the end of the initial term.

An attractive remuneration package will be negotiated with the successful candidate including 17% superannuation.  

Position Description

Download File New_503000_ChairImmunology_RecruitmentBooklet.pdf


For a confidential discussion about this position please contact:

Jenny Sutton

Partner, Odgers Berndtson

Phone: +61 402548703


Applications will close on Thursday 10th May 2018.

Interviews with shortlisted candidates are likely to be held around mid-June 2018.

To apply for this role please do not use the Apply button. Applications should be emailed directly to